| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2010PLoSO...512965M |
| P356 | DOI | 10.1371/JOURNAL.PONE.0012965 |
| P932 | PMC publication ID | 2945761 |
| P698 | PubMed publication ID | 20885974 |
| P5875 | ResearchGate publication ID | 47157606 |
| P50 | author | Jacob Madsen | Q27114895 |
| Liselotte Højgaard | Q28520613 | ||
| Fredrik Björkling | Q57189486 | ||
| Andreas Kjær | Q39183738 | ||
| P2093 | author name string | Maxwell Sehested | |
| Peter Buhl Jensen | |||
| Kamille Dumong Erichsen | |||
| Mette Munk Jensen | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| A new mathematical model for relative quantification in real-time RT-PCR | Q27860781 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Mammalian deoxyribonucleoside kinases | Q28111474 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine | Q28318354 | ||
| Regulation of human thymidine kinase during the cell cycle | Q28622470 | ||
| Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors | Q33231305 | ||
| Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper | Q33377242 | ||
| Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer | Q33641143 | ||
| 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. | Q34211088 | ||
| Human thymidine kinase 1. Regulation in normal and malignant cells | Q34296535 | ||
| Syntheses and antiproliferative evaluation of oxyphenisatin derivatives | Q34577907 | ||
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography | Q35596074 | ||
| Monitoring primary breast cancer throughout chemotherapy using FDG-PET. | Q53525219 | ||
| In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. | Q53526226 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells | Q72135936 | ||
| RNA integrity and the effect on the real-time qRT-PCR performance | Q36392323 | ||
| Monitoring chemotherapy and radiotherapy of solid tumors | Q36474962 | ||
| Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer | Q37132173 | ||
| (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. | Q39838114 | ||
| Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models | Q40245264 | ||
| Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. | Q40474923 | ||
| Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. | Q40582151 | ||
| Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT). | Q41840410 | ||
| Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. | Q44128080 | ||
| In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumor | Q44214948 | ||
| Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography | Q44366483 | ||
| Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. | Q44576349 | ||
| Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. | Q44836743 | ||
| Impact of animal handling on the results of 18F-FDG PET studies in mice. | Q46109682 | ||
| The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels | Q46404885 | ||
| Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo | Q46495676 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| xenograft | Q64148587 | ||
| Fluorodeoxyglucose Positron Emission Tomography | Q130273243 | ||
| P304 | page(s) | e12965 | |
| P577 | publication date | 2010-09-24 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice | |
| P478 | volume | 5 |
| Q35120054 | 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice |
| Q34278079 | 18FDG, [18F]FLT, [18F]FAZA, and 11C-methionine are suitable tracers for the diagnosis and in vivo follow-up of the efficacy of chemotherapy by miniPET in both multidrug resistant and sensitive human gynecologic tumor xenografts |
| Q38937295 | Apoptosis imaging studies in various animal models using radio-iodinated peptide. |
| Q36500372 | Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy |
| Q33889809 | FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study |
| Q41323772 | Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism. |
| Q92758650 | Gut butyrate-producing organisms correlate to Placenta Specific 8 protein: Importance to colorectal cancer progression |
| Q35081130 | Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET |
| Q36988052 | Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging |
| Q26778463 | Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies |
| Q38202189 | PET/CT in therapy evaluation of patients with lung cancer |
| Q39498230 | PET/MRI in cancer patients: first experiences and vision from Copenhagen |
| Q36589159 | Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer |
| Q33706877 | Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma |
| Q38775709 | Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review |
| Q26775959 | Predictive factors of response to mTOR inhibitors in neuroendocrine tumours |
| Q36335296 | Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring |
| Q36894808 | [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941. |
| Q55286904 | [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. |
| Q34645445 | [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice |
| Q34505642 | [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice |
| Q28484852 | [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts |
| Q60606978 | [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner |
Search more.